Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused pipeline and progress across multiple clinical-stage assets. The firm views Ascentage’s approach to addressing drug resistance in blood cancers as a key driver of upside as its next-generation programs advance toward clinical validation.

On February 5, 2026, Ascentage Pharma Group International (NASDAQ:AAPG) announced that its next-generation BTK-targeted protein degrader, APG-3288, received investigational new drug clearance from China’s Center for Drug Evaluation, shortly after securing a similar clearance from the U.S. FDA. The company plans to initiate a multicenter Phase I trial in patients with relapsed or refractory hematologic malignancies. Unlike traditional BTK inhibitors, APG-3288 uses PROTAC technology to degrade both wild-type and mutant BTK, potentially overcoming resistance seen with existing therapies. For investors, the dual IND clearances meaningfully de-risk the program and support faster global clinical development.

Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers and age-related diseases. Founded in 2009, the company is headquartered in Suzhou, China. Ascentage Pharma is one of the 10 best long term healthcare stocks to buy.

While we acknowledge the potential of AAPG as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.